Extended Data Fig. 4: Quantitative HLA metrics fail to predict ICB outcome in Leuven cohort.
a, Bar chart representing overall response rate (ORR), showing complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) and not evaluable (NA), by HLA class I expression (dichotomized by optimal statistical cutoff for overall survival (OS), also for panel b and c). Two-sided p-value as calculated by Fisher Exact test. b-c, Kaplan-Meier curves showing progression-free survival (PFS) (b) and OS (c) stratified by HLA class I expression. d, Bar chart representing ORR by HLA class II expression (dichotomized by optimal statistical cutoff for OS, also for panel e and f). Two-sided p-value as calculated by Fisher Exact test. e, f, Kaplan-Meier curve showing PFS (e), and OS (f) stratified by HLA class II expression. g, Bar chart representing ORR by HLA heterozygosity (dichotomized by <= 10 vs. 11-12, also for panel h and I). Two-sided p-value as calculated by Fisher Exact test. h, i, Kaplan-Meier curve showing PFS (h), and OS (i) stratified by HLA heterozygosity. j, Bar chart representing ORR by HLA A*03 allele carrier status. Two-sided p-value as calculated by Fisher Exact test. k-l, Kaplan-Meier curve showing PFS (k), and OS (l) stratified by HLA A*03 allele carrier status. m, Bar chart representing ORR by HLA evolutionary divergence (HED), dichotomized by highest quartile (also for panel n and o). Two-sided p-value as calculated by Fisher Exact test. n-o, Kaplan-Meier curve showing PFS (n), and OS (o) stratified by HLA HED. Hazard ratio (HR), 95% confidence interval and two-sided p-values as calculated by Cox proportional hazard models, both univariate (UVA) as well as multivariate (MVA) adjusting for age and IMDC risk group.
